Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic

Background: Mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may reduce the efficacy of neutralizing monoclonal antibody therapy against coronavirus disease 2019 (COVID-19). We here evaluated the efficacy of casirivimab-imdevimab in patients with mild-to-moderate COVID-19 du...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Yasuhito, Shibata, Yoko, Minemura, Hiroyuki, Nikaido, Takefumi, Tanino, Yoshinori, Fukuhara, Atsuro, Kanno, Ryuzo, Saito, Hiroyuki, Suzuki, Shuzo, Ishii, Taeko, Inokoshi, Yayoi, Sando, Eiichiro, Sakuma, Hirofumi, Kobayashi, Tatsuho, Kume, Hiroaki, Kamimoto, Masahiro, Aoki, Hideko, Takama, Akira, Kamiyama, Takamichi, Nakayama, Masaru, Saito, Kiyoshi, Tanigawa, Koichi, Sato, Masahiko, Kanbe, Toshiyuki, Kanzaki, Norio, Azuma, Teruhisa, Sakamoto, Keiji, Nakamura, Yuichi, Ohtani, Hiroshi, Waragai, Mitsuru, Maeda, Shinsaku, Ishida, Tokiya, Sugino, Keishi, Tsukada, Yasuhiko, Yamada, Ryuki, Sato, Riko, Onuma, Takumi, Tomita, Hikaru, Saito, Mikako, Watanabe, Natsumi, Rikimaru, Mami, Kawamata, Takaya, Umeda, Takashi, Morimoto, Julia, Togawa, Ryuichi, Sato, Yuki, Saito, Junpei, Kanazawa, Kenya, Iseki, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149641/
https://www.ncbi.nlm.nih.gov/pubmed/35693744
http://dx.doi.org/10.7150/ijms.71132

Ejemplares similares

Ejemplares similares